Masimo Announces 510(k) Clearance for O3™ Regional Oximetry

Masimo Root with O3 Regional Oximetry and SedLine Brain Function Monitoring
share Share
Masimo has announced FDA 510(k) clearance for O3™ regional oximetry. Regional oximetry, also referred to as tissue or cerebral oximetry, may help clinicians monitor cerebral oxygenation in situations in which pulse oximetry alone may not be fully indicative of the oxygen in the brain due to various factors, such as the type of clinical procedure being performed.

O3 regional oximetry uses near-infrared spectroscopy (NIRS) to continuously monitor absolute and trended regional tissue oxygen saturation (rSO2) in the cerebral region. In a study on 27 subjects published inAnesthesia and Analgesia in 2014, Dr. Daniel Redford of theUniversity of Arizonacompared cerebral oxygen saturation measurements obtained from O3 with saturations obtained from blood samples (SavO2) through induced hypoxia.1 O3 regional oximetry provided absolute root-mean-squared error of 4% and relative root-mean-squared error of 2.1%.1 This study did not require that end tidal carbon dioxide (EtCO2) levels be fixed in the study protocol, allowing the rSO2 measurement to be responsive to changes in tissue oxygen saturation due to changes in CO2 in the blood. Follow up studies with O3 extended the subject pool to 74 subjects and demonstrated that O3 maintained its absolute and relative accuracy.2

“O3 regional oximetry delivers again on Masimo's technical prowess and gives clinicians access to valuable, accurate data about cerebral oxygen saturation,” stated Joe Kiani, Founder and CEO of Masimo. “With the addition of O3 regional oximetry to the Root platform, clinicians can simultaneously access rSO2 and other measurements including SedLine brain function monitoring, Masimo SET SpO2, PVI, and SpHb monitoring – all in one monitoring platform.”

O3 regional oximetry is currently intended for use with adults weighing 40 kg (88 lbs) or greater.


  1.   Redford D, Paidy S, Kashif F. Absolute and Trend Accuracy of a New Regional Oximeter in Healthy Volunteers During Controlled Hypoxia. Anesth Analg. 2014 Dec;119(6):1315-1319.
2.Masimo FDA submission data on file.
Source & Image Credit: Masimo

«« 6 Ways to Improve Medical Emergency Team Performance

Evidence-Based Design Drives New Finnish ICU »»

Published on : Mon, 13 Jun 2016

Related Articles
New SunTech Medical CT40 Vital Signs Device to Feature Masimo SET® Pulse Oximetry Technology

Masimo and   SunTech Medical, a Halma (LSE:HLMA) company, jointly has announced the integration of Masimo SET® pulse oximetry... Read more

Masimo Root with Radius-7 with rainbow

Radius-7 is the First Wearable, Tetherless, Noninvasive rainbow® Monitor Masimo  has announced FDA 510(k) clearance for... Read more

One of the World’s Leading Centers for Cardiovascular Medicine & Transplantation Adopts Masimo’s SedLine® Brain Function Monitoring and O3™ Regional Oximetry

Masimo  has announced  that Deutsches Herzzentrum Berlin (DHZB / German Heart Center Berlin) in Berlin, Germany, has adopted... Read more

Masimo,Oximetry,SedLine, Brain Function Monitoring Masimo (NASDAQ: MASI) has announced FDA 510(k) clearance for O3™ regional oximetry

No comment

Please login to leave a comment...

Highlighted Products